FNCH - Finch Therapeutics to cut workforce by 20%
Finch Therapeutics (NASDAQ:FNCH) said Tuesday it plans to reduce its workforce by ~20%. The move will allow FNCH to focus its financial resources on its wholly-owned programs - recurrent C. difficile infection and autism spectrum disorder development programs - and its work with Takeda in inflammatory bowel disease. The job cuts follow FNCH pausing its chronic hepatitis B program after the FDA issued a clinical hold on its investigational new drug application for CP101. FNCH recently submitted a complete response to the FDA regarding the clinical hold, which is related to its SARS-CoV-2 donor screening protocols, and is awaiting feedback. FNCH stock rose 2.4% premarket on Tuesday.
For further details see:
Finch Therapeutics to cut workforce by 20%